Vident Advisory LLC Lowers Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Vident Advisory LLC reduced its stake in Jazz Pharmaceuticals by 10.4%, now holding 26,209 shares valued at approximately $3.25 million.
• Several institutional investors, including Nuveen LLC and Fuller & Thaler Asset Management Inc., have increased their positions in Jazz Pharmaceuticals, reflecting strong institutional interest.
• Analysts have mixed sentiments on Jazz Pharmaceuticals, with some upgrades and downgrades resulting in the stock's current consensus rating of "Moderate Buy" and a consensus price target of $178.67.

Vident Advisory LLC lowered its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 10.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 26,209 shares of the specialty pharmaceutical company's stock after selling 3,053 shares during the period. Vident Advisory LLC's holdings in Jazz Pharmaceuticals were worth $3,254,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in JAZZ. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals in the 1st quarter worth $25,000. Elequin Capital LP lifted its position in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares during the period. Parallel Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after purchasing an additional 119 shares during the period. Picton Mahoney Asset Management lifted its position in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock worth $34,000 after purchasing an additional 269 shares during the period. Finally, Spire Wealth Management lifted its position in shares of Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after purchasing an additional 161 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded down $3.70 during trading hours on Thursday, hitting $128.02. 941,067 shares of the company's stock traded hands, compared to its average volume of 948,294. The business's fifty day moving average price is $115.82 and its two-hundred day moving average price is $117.12. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $7.77 billion, a P/E ratio of -19.02, a P/E/G ratio of 8.04 and a beta of 0.24. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on JAZZ. Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research report on Thursday, August 28th. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Needham & Company LLC reissued a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $178.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.